Nursing Medical News about hormone therapy memory

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women
Psychoneuroendocrinology, 07/01/09

Tierney MC et al. - These results suggest that benefits of estrogen exposure may be limited to those with average to above average scores on the delayed verbal recall. HT dose and formulation may have contributed to these beneficial outcomes. Replication is warranted before recommendations can be made in the clinical setting.

Methods

2-year, randomized, double-blind, placebo-controlled trial of 142 women aged 61–87, randomly assigned to receive 1 mg 17-β estradiol daily and 0.35 mg norethindrone 3 days/week or daily placebo for 2 years.
The primary outcome was short-delay verbal recall of the California Verbal Learning Test (CVLT).
To look for differences in response to HT by baseline short-delay recall, this study examined the primary outcome in participants grouped according to whether their baseline scores were below average for the age group or greater than or equal to this score and according to whether they met criteria for Mild Cognitive Impairment (MCI) or not.

Results

133 women completed 1 year of the trial and 128 completed 2 years.
Prespecified covariates in all repeated measures analyses of covariance (RANCOVA) included age, education, APOE 4, and prior HT use.
RANCOVA showed no overall significant treatment effects at year 1 or year 2.
After testing for an interaction, which was significant (p = 0.02), we found that women in the HT group who scored at or above the average showed significantly less decline than the placebo group in short-delay verbal recall after 1 year, p = 0.007 and 2 years, p = 0.01.
No treatment effects were found in women below the average in either year.
When grouped according to whether the participant met criteria for MCI, the interaction between treatment group and MCI subgroup was not significant.

<< Previous
Declining health insurance access among US hispanic workers: Not...

Next >>
Cardiovascular Effects of Longer-Term, High-Dose OROS...